Feasibility of immunotherapy in cancer patients with persistent or past hepatitis B or C virus infection.

Tasuku NakaboriYutaro AbeSena HigashiTakeru HiraoYasuharu KawamotoShingo MaedaKazuma DaikuMakiko UrabeYugo KaiRyoji TakadaTakuo YamaiKenji IkezawaHiroyuki UeharaKazuyoshi Ohkawa

Published in: JGH open : an open access journal of gastroenterology and hepatology (2022)

Immunotherapy is feasible for most cancer patients with chronic HBV or HCV infection; however, liver function and virological markers should be carefully monitored in treatment-naïve patients, especially those with HCV infection, during ICI treatment.

Keyphrases

hepatitis c virus
end stage renal disease
newly diagnosed
hepatitis b virus
chronic kidney disease
ejection fraction
human immunodeficiency virus
peritoneal dialysis
papillary thyroid
hiv infected
young adults
hiv infected patients